Table 1.
The TARGET protocol will collect information about a series of characteristics and tests along the clinical evolution of patients with COVID-19. At each time point, the following data will be assessed.
| Data registered | Day 0 | Day 3 | Day 9 | Day 18 |
| Age, gender, weight, and height | ✓a | —b | — | — |
| Symptoms | ✓ | ✓ | ✓ | ✓ |
| Contact with SARS-CoV-2 patient | ✓ | — | — | — |
| Reverse transcription polymerase chain reaction | ✓ | — | — | — |
| Time of symptoms | ✓ | — | — | — |
| Comorbidities | ✓ | — | — | — |
| Medications in use | ✓ | ✓ | ✓ | ✓ |
| SpO2 | ✓ | ✓ | ✓ | ✓ |
| Thorax computed tomography | ✓ | ✓ | ✓ | ✓ |
| Biochemical tests | ✓ | ✓ | ✓ | ✓ |
| Supplementary oxygen | ✓ | ✓ | ✓ | ✓ |
| Mechanical ventilation | ✓ | ✓ | ✓ | ✓ |
| Death | ✓ | ✓ | ✓ | ✓ |
| COVID-19 treatment | ✓ | ✓ | ✓ | ✓ |
| Immune biomarkers | ✓ | ✓ | ✓ | — |
| Leukocyte phenotyping | ✓ | ✓ | ✓ | — |
| Cortisol/prolactin levels | ✓ | ✓ | ✓ | ✓ |
| Immunoglobulin profile | — | ✓ | — | — |
| D-dimer | — | — | ✓ | — |
| Thromboelastometry | — | — | ✓ | — |
| Neutralizing antibodies | — | — | — | ✓ |
| Metabolomic analysis | ✓ | ✓ | ✓ | ✓ |
| Gene expression | — | ✓ | ✓ | — |
| Neutrophils | — | — | ✓ | — |
aIndicates data was registered at this time point.
bIndicates data was not registered at this time point.